Literature DB >> 19595269

Minocycline-induced skin pigmentation: an update.

Aanand N Geria1, Ani L Tajirian, George Kihiczak, Robert A Schwartz.   

Abstract

Minocycline is a commonly used antibiotic for long-term treatment of acne vulgaris. A well-documented and cosmetically dis-pleasing side effect is skin pigmentation. Three distinct types occur: Type I, blue-black/grey pigment on the face in areas of scarring or inflammation associated with acne; type II, blue-grey pigment on normal skin on the shins and forearms; type III, diffuse muddy-brown discoloration in areas of sun exposure. Types I and II stain for iron and melanin extracellularly and within macrophages in the dermis. Type III shows nonspecific increased melanin in basal keratinocytes and dermal melanophages staining for melanin only. The etiology of this pigmentation is unknown, but may be related to polymerized reactive metabolites, insoluble chelation products, and lengthy treatment durations of minocycline compared to other tetracyclines. Types I and II tend to resolve slowly over time, whereas type III persists indefinitely. Treatment involves early recognition, discontinuation of the drug, sun protection, and laser for persistent pigmentation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19595269

Source DB:  PubMed          Journal:  Acta Dermatovenerol Croat        ISSN: 1330-027X            Impact factor:   1.256


  17 in total

1.  Minocycline-induced skin pigmentation.

Authors:  Tetsuro Kobayashi; Kayoko Hayakawa
Journal:  Infection       Date:  2016-10-17       Impact factor: 3.553

2.  Minocycline-Induced Blue-Gray Discoloration.

Authors:  Michelangelo La Placa; Salvatore Domenico Infusino; Riccardo Balestri; Colombina Vincenzi
Journal:  Skin Appendage Disord       Date:  2017-04-22

3.  Type 2 Minocycline-induced hyperpigmentation successfully treated with the novel 755 nm picosecond alexandrite laser - a case report.

Authors:  Katsumi Sasaki; Toshio Ohshiro; Takafumi Ohshiro; Reiko Sakio; Emi Fukazawa; Masahiro Toriumi; Tamotsu Ebihara
Journal:  Laser Ther       Date:  2017-06-30

4.  Warfarin, head injury and bruising.

Authors:  Marc Wallace; Emma D'Amato; Jasroop Chana; Antoni Chan
Journal:  BMJ Case Rep       Date:  2010-03-15

5.  Minocycline-induced attenuation of iron overload and brain injury after experimental intracerebral hemorrhage.

Authors:  Fan Zhao; Ya Hua; Yangdong He; Richard F Keep; Guohua Xi
Journal:  Stroke       Date:  2011-10-13       Impact factor: 7.914

6.  Type II minocycline-induced cutaneous and scleral hyperpigmentation.

Authors:  Zaw Min; Vikram Saini; Charles E Mount; Nitin Bhanot
Journal:  Intern Emerg Med       Date:  2021-09-21       Impact factor: 3.397

Review 7.  New antiepileptic medication linked to blue discoloration of the skin and eyes.

Authors:  Sarah Clark; Alexandra Antell; Kimberly Kaufman
Journal:  Ther Adv Drug Saf       Date:  2015-02

8.  Interaction and efficacy of Keigai-rengyo-to extract and acupuncture in male patients with acne vulgaris: a study protocol for a randomized controlled pilot trial.

Authors:  Kyu Seok Kim; Yoon-Bum Kim
Journal:  Trials       Date:  2011-03-19       Impact factor: 2.279

9.  Antibiotic precautions in athletes.

Authors:  Kristopher Fayock; Matthew Voltz; Bradley Sandella; Jeremy Close; Matthew Lunser; Joshua Okon
Journal:  Sports Health       Date:  2014-07       Impact factor: 3.843

10.  The peculiar case of a blue man.

Authors:  A Biswas
Journal:  J Postgrad Med       Date:  2015 Apr-Jun       Impact factor: 1.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.